InvestSMART

Immutep Limited (ASX: IMM) - Announcements

- Current share price for IMM : $0.023

ASX company news and announcements for Immutep Limited (IMM) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Immutep Limited (IMM) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Immutep Limited (IMM), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Immutep Limited (IMM)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$34 Annual Report to shareholders 21 Oct 2022 2:21PM $0.290 $0.023 fallen by 92.07%
$34 Change in substantial holding 18 Oct 2022 8:08AM $0.305 $0.023 fallen by 92.46%
$34 Application for quotation of securities - IMM 13 Oct 2022 9:11AM $0.280 $0.023 fallen by 91.79%
$34 Ceasing to be a substantial shareholder from AEF 6 Oct 2022 11:07AM $0.255 $0.023 fallen by 90.98%
$34 Abstracts accepted for Presentation at SITC 2022 6 Oct 2022 8:14AM $0.250 $0.023 fallen by 90.80%
$34 Change of Director's Interest Notice - P Meyers 5 Oct 2022 5:24PM $0.250 $0.023 fallen by 90.80%
$34 Change of Director's Interest Notice - M Voigt 5 Oct 2022 5:24PM $0.250 $0.023 fallen by 90.80%
$34 Change of Director's Interest Notice - F Triebel 5 Oct 2022 5:22PM $0.250 $0.023 fallen by 90.80%
$34 Fast Track granted by US FDA for Efti in 1st line NSCLC 4 Oct 2022 9:53AM $0.240 $0.023 fallen by 90.42%
$34 Application for quotation of securities - IMM 3 Oct 2022 11:49AM $0.235 $0.023 fallen by 90.21%
$34 Becoming a substantial holder from AEF 30 Sep 2022 10:47AM $0.245 $0.023 fallen by 90.61%
$34 Immutep to Participate in Two Upcoming Investor Conferences 26 Sep 2022 8:13AM $0.260 $0.023 fallen by 91.15%
$34 Immutep Receives A$2.7 million R&D French Tax Incentive 23 Sep 2022 9:09AM $0.265 $0.023 fallen by 91.32%
$34 2022 AGM & Key Dates 21 Sep 2022 9:09AM $0.270 $0.023 fallen by 91.48%
$34 Clinical Development Update for Eftilagimod Alpha 14 Sep 2022 8:14AM $0.265 $0.023 fallen by 91.32%
$34 Initial Director's Interest Notice - Frederic Triebel 13 Sep 2022 8:15AM $0.265 $0.023 fallen by 91.32%
$34 Immutep Appoints LAG-3 Pioneer Dr Frederic Triebel to Board 13 Sep 2022 8:14AM $0.265 $0.023 fallen by 91.32%
$34 New investigator-initiated ph2 trial in Soft Tissue Sarcoma 6 Sep 2022 9:21AM $0.275 $0.023 fallen by 91.64%
$34 Appendix 4E & 2022 Full Year Statutory Accounts 31 Aug 2022 5:35PM $0.285 $0.023 fallen by 91.93%
$34 Japanese Patent Grant for efti, soluble LAG-3 with anti-PD-1 30 Aug 2022 9:43AM $0.280 $0.023 fallen by 91.79%
$34 TACTI-002 2nd line lung cancer data presented at 2022 WCLC 1 Aug 2022 7:55AM $0.340 $0.023 fallen by 93.24%
$34 Quarterly Activities/Appendix 4C Cash Flow Report 28 Jul 2022 10:07AM $0.330 $0.023 fallen by 93.03%
$34 Notification of cessation of securities - IMM 14 Jul 2022 5:25PM $0.320 $0.023 fallen by 92.81%
$34 Immutep granted Japanese Patent for IMP761 6 Jul 2022 8:22AM $0.315 $0.023 fallen by 92.70%
$34 TACTI-002 lung cancer data to be presented at 2022 WCLC 27 Jun 2022 9:29AM $0.320 $0.023 fallen by 92.81%

351 - 375 of 798 results

Page 15 of 32

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.